MX366912B - Producción de vacuna recombinante en e. coli mediante conjugación enzimática. - Google Patents
Producción de vacuna recombinante en e. coli mediante conjugación enzimática.Info
- Publication number
- MX366912B MX366912B MX2015005797A MX2015005797A MX366912B MX 366912 B MX366912 B MX 366912B MX 2015005797 A MX2015005797 A MX 2015005797A MX 2015005797 A MX2015005797 A MX 2015005797A MX 366912 B MX366912 B MX 366912B
- Authority
- MX
- Mexico
- Prior art keywords
- coli
- production
- recombinant vaccine
- enzymatic conjugation
- glycoconjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una bacteria Gram-negativa diseñada para la producción de polisacárido, dicha bacteria Gram-negativa está caracterizada porque comprende (a) a un ácido nucleico que codifica un gen regular wzg, wzh, wzd o wze de ubn complejo génico de polisacárido capsular de S. pneumoniae CPS1, CPES2, CPS3, CPS4, CPS5, CPS6 (A y B) , CPS7 (A, B, C), CPS8, CPS9 (A, L, N, V, ), CPS10 (A, B, C, F,) CPS11 (A,B,C,D,F,) CPS12 (A, B,F) , CPS13, CPS14 CPS15 (A, B,C,F), CPS16 (A,F), CPS17 (A, F), CPS18 (A, B, F), CPS19 (A,B, C, F) CPS20, CPS21, CPS22 (A,F) CPS23 (A,B,F), CPS24 (A,B,F), CPS25 (A, F) CPS26, CPS27, CPS28 (A,F) CPS29, CPS31, CPS32 (A,F) CPS33 (A, B,C,D,F), CPS34, CPS35 (A, B,C,D,F,) CPS36, CPS37, CPS38, CPS39, CPS40, CPS41 (A,F)CPS42, CPS43, CPS44, CPS45, CPS46, CPS47 (A,F), o CPS48; o (b) un ácido nucleico que codifica un gen regulador capA, capB o capC de un complejo génico de polisacárido capsular de Staphylococcus auereus CPS5, o CPS8; o (c) un ácido nucleico que codifica un gen regulador CpsA, CpsB, CpsC o CpsD de un complejo génico de polisacárido capsular de Streptococcus agalactiae (grupo B, GBS) CPSIa, CPSlb, CPSII, CPSIII, CPSIV, CPSV, CPSVI, CPSVII, O CPSVIII, en donde la bacteria Gramj-negativa además comprende una oligosacaril-transferasa la cual es heterólogo para la bacteria Gram-negativa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723408P | 2012-11-07 | 2012-11-07 | |
| PCT/EP2013/073266 WO2014072405A1 (en) | 2012-11-07 | 2013-11-07 | Production of recombinant vaccine in e. coli by enzymatic conjugation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015005797A MX2015005797A (es) | 2016-03-09 |
| MX366912B true MX366912B (es) | 2019-07-30 |
Family
ID=49552366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005797A MX366912B (es) | 2012-11-07 | 2013-11-07 | Producción de vacuna recombinante en e. coli mediante conjugación enzimática. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150273043A1 (es) |
| EP (3) | EP3508579B1 (es) |
| JP (2) | JP6412875B2 (es) |
| KR (1) | KR20150079964A (es) |
| CN (1) | CN105008539B (es) |
| AU (2) | AU2013343520B2 (es) |
| BR (1) | BR112015010283A8 (es) |
| CA (2) | CA2889767C (es) |
| EA (1) | EA201590705A1 (es) |
| ES (3) | ES2713166T3 (es) |
| IL (1) | IL238586A0 (es) |
| MX (1) | MX366912B (es) |
| SG (1) | SG11201503308XA (es) |
| TR (1) | TR201903066T4 (es) |
| WO (1) | WO2014072405A1 (es) |
| ZA (1) | ZA201503097B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2780487C (en) * | 2009-11-19 | 2019-05-21 | Glycovaxyn Ag | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| JP2016533719A (ja) | 2013-10-11 | 2016-11-04 | グリコヴァキシン アーゲー | 宿主細胞改変方法 |
| DK3110441T5 (da) | 2014-02-24 | 2024-10-14 | Glaxosmithkline Biologicals Sa | Hidtil ukendt polysaccharid og anvendelser deraf |
| JP6682451B2 (ja) * | 2014-04-17 | 2020-04-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 改変型宿主細胞およびその使用 |
| SG11201700325SA (en) * | 2014-08-08 | 2017-02-27 | Glycovaxyn Ag | Modified host cells and hybrid oligosaccharides for use in bioconjugate production |
| AU2016224006B8 (en) * | 2015-02-26 | 2020-03-19 | Vaxnewmo Llc | Acinetobacter O-oligosaccharyltransferases and uses thereof |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| CN105963691B (zh) * | 2016-07-03 | 2020-05-01 | 查文娟 | 一种肺炎链球菌疫苗 |
| CN106929573B (zh) * | 2017-02-21 | 2020-06-09 | 南开大学 | 对嗜肺军团菌O12型的wzm和wecA基因特异的核苷酸序列及其应用 |
| GB201712678D0 (en) * | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| WO2019043245A1 (en) * | 2017-09-04 | 2019-03-07 | London School Of Hygiene And Tropical Medicine | MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES |
| EP3703745B1 (en) | 2017-11-04 | 2024-04-10 | Nevada Research & Innovation Corporation | Immunogenic conjugates and methods of use thereof |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| EP3806881A4 (en) | 2018-06-16 | 2022-07-27 | Vaxnewmo Llc | GLYCOSYLATED COMP-PILIN VARIANTS, METHOD OF MANUFACTURE AND USES THEREOF |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| EP3650044A1 (en) * | 2018-11-06 | 2020-05-13 | ETH Zürich | Anti-glycan vaccines |
| US20220088211A1 (en) * | 2018-12-21 | 2022-03-24 | Vaxnewmo Llc | O-linked glycosylation recognition motifs |
| EP3942028B9 (en) | 2019-03-18 | 2023-08-23 | Janssen Pharmaceuticals, Inc. | Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| CN111518738B (zh) * | 2020-05-08 | 2022-02-08 | 徐州海润生物科技有限公司 | 重组卡介苗及其制备方法和应用 |
| CN112369722B (zh) | 2020-05-08 | 2023-03-17 | 湖北中烟工业有限责任公司 | 加热不燃烧装置和温度控制方法 |
| EP4171625A2 (en) | 2020-06-25 | 2023-05-03 | GlaxoSmithKline Biologicals SA | Klebsiella pneumoniae o-antigen vaccine |
| CN119454928A (zh) | 2020-09-17 | 2025-02-18 | 杨森制药公司 | 多价疫苗组合物及其用途 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
| GB202302579D0 (en) | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995031548A1 (en) * | 1994-05-16 | 1995-11-23 | The Uab Research Foundation | Streptococcus pneumoniae capsular polysaccharide genes and flanking regions |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US7541043B2 (en) | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
| KR20090110951A (ko) | 2002-03-07 | 2009-10-23 | 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 | 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계 |
| PT1888761E (pt) | 2005-05-11 | 2011-01-03 | Eth Zuerich | Proteínas n-glicosiladas recombinantes de células procarióticas |
| KR20100123730A (ko) | 2008-02-20 | 2010-11-24 | 글리코박신 아게 | 원핵생물 세포로부터의 ｎ-당화된 재조합 단백질로부터 제조된 바이오컨쥬게이트 |
| WO2010110931A2 (en) | 2009-03-23 | 2010-09-30 | The Brigham And Women's Hospital, Inc. | Glycoconjugate vaccines |
| CA2768263C (en) | 2009-07-17 | 2015-05-12 | Ocean Harvest Technology (Canada) Inc. | Natural and sustainable seaweed formula that replaces synthetic additives in fish feed |
| HUE037956T2 (hu) | 2010-05-06 | 2018-09-28 | Glaxosmithkline Biologicals Sa | Kapszuláris Gram-pozitív bakteriális biokonjugátum vakcinák |
| CN110423716A (zh) * | 2012-10-12 | 2019-11-08 | 葛兰素史密丝克莱恩生物有限公司 | 宿主细胞修饰方法 |
-
2013
- 2013-11-07 MX MX2015005797A patent/MX366912B/es active IP Right Grant
- 2013-11-07 ES ES13788753T patent/ES2713166T3/es active Active
- 2013-11-07 WO PCT/EP2013/073266 patent/WO2014072405A1/en active Application Filing
- 2013-11-07 BR BR112015010283A patent/BR112015010283A8/pt not_active Application Discontinuation
- 2013-11-07 AU AU2013343520A patent/AU2013343520B2/en active Active
- 2013-11-07 ES ES18198665T patent/ES2848774T3/es active Active
- 2013-11-07 CA CA2889767A patent/CA2889767C/en active Active
- 2013-11-07 EP EP18211761.4A patent/EP3508579B1/en active Active
- 2013-11-07 JP JP2015541130A patent/JP6412875B2/ja active Active
- 2013-11-07 EA EA201590705A patent/EA201590705A1/ru unknown
- 2013-11-07 KR KR1020157014830A patent/KR20150079964A/ko not_active Application Discontinuation
- 2013-11-07 SG SG11201503308XA patent/SG11201503308XA/en unknown
- 2013-11-07 US US14/440,311 patent/US20150273043A1/en not_active Abandoned
- 2013-11-07 EP EP13788753.5A patent/EP2917351B1/en active Active
- 2013-11-07 ES ES18211761T patent/ES2882282T3/es active Active
- 2013-11-07 TR TR2019/03066T patent/TR201903066T4/tr unknown
- 2013-11-07 CN CN201380069524.XA patent/CN105008539B/zh active Active
- 2013-11-07 EP EP18198665.4A patent/EP3444352B1/en active Active
- 2013-11-07 CA CA3125293A patent/CA3125293A1/en active Pending
-
2015
- 2015-05-03 IL IL238586A patent/IL238586A0/en unknown
- 2015-05-06 ZA ZA2015/03097A patent/ZA201503097B/en unknown
-
2017
- 2017-12-20 AU AU2017279688A patent/AU2017279688B2/en active Active
-
2018
- 2018-07-13 US US16/034,906 patent/US10973901B2/en active Active
- 2018-10-01 JP JP2018186302A patent/JP6833785B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX366912B (es) | Producción de vacuna recombinante en e. coli mediante conjugación enzimática. | |
| ZA201601534B (en) | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses | |
| SG10201900948PA (en) | Modified nucleotide linkers | |
| MY191370A (en) | Production of odd chain fatty acid derivatives in recombinant microbial cells | |
| MX363512B (es) | Proceso de glicoconjugacion. | |
| EP4279579A3 (en) | Methods and compositions for natural killer cells | |
| EP4253395A3 (en) | Processes for the preparation of carbohydrate conjugated rna agents | |
| MX2013009175A (es) | Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas. | |
| MX2013004353A (es) | Produccion recombinante de n-propanol e isopropanol. | |
| MX2014001383A (es) | Colageno 7 y metodos relacionados. | |
| IN2014DN06104A (es) | ||
| IN2015DN03322A (es) | ||
| SG10201809452RA (en) | Cell culture compositions with antioxidants and methods for polypeptide production | |
| PH12014501556A1 (en) | Microorganism able to produce l-amino acid, and method for producing l-amino acid by using same | |
| IN2012DN02210A (es) | ||
| MY182946A (en) | Production of organic acids by fermentation at low ph | |
| IN2015DN03206A (es) | ||
| MX2020001357A (es) | Produccion microbiana de aminas grasas. | |
| GB201017519D0 (en) | Vaccines | |
| MX358132B (es) | Solucion de trombina y metodos de uso de esta. | |
| IN2012DN02760A (es) | ||
| MX2012007283A (es) | Composiciones para vacunas. | |
| MX2014007760A (es) | Bacterias con unidades transcripcionales reconstruidas y los usos de las mismas. | |
| MX2013005749A (es) | Composiciones y metodos para producir enterocinasa en levaduras. | |
| WO2015117033A3 (en) | Methods of increasing protein production in mammalian cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. |
|
| FG | Grant or registration |